Kalaris Therapeutics KLRS Income Statement (2019-2026)

NASDAQ KLRS
$4.12 -0.05 (-1.20%)
At close: Aug 20, 2026 · 4:00 PM EDT
Income Statement Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity) (Quarter)
2.75M2.76M2.79M2.82M4.03M3.33M4.06M4.11M4.96M4.96M5.00M5.01M5.02M5.01M4.05M18.70M18.70M15.27M22.99M23.80M
Operating items
Research & Development (Quarter)
33.06M41.60M29.07M31.38M30.00M28.42M30.72M34.82M34.16M33.37M0.02M3.21M36.02M-0.21M0.15M0.35M0.23M30.03M7.57M9.02M
Selling, General & Administrative (Quarter)
12.44M14.19M14.13M13.24M12.95M12.01M12.51M12.48M12.80M10.46M0.60M0.98M1.83M3.28M4.32M3.82M3.62M3.64M4.26M3.37M
Restructuring Costs (Quarter)
0.39M0.42M1.25M2.69M3.65M2.72M2.48M2.10M2.70M2.15M
Other Operating Expenses (Quarter)
18.57M-0.25M-0.42M-1.25M-35.63M-9.72M5.37M-7.17M-36.58M-15.51M-2.15M
Operating Expenses (Quarter)
45.50M55.80M43.19M44.62M42.95M40.43M43.23M47.30M46.96M62.41M0.77M4.19M37.85M-29.86M-1.60M12.26M-0.85M-0.80M-0.98M12.39M
Operating Income (Quarter)
-45.50M-55.80M-43.19M-44.62M-42.95M-40.43M-43.23M-47.30M-46.96M-62.41M-2.56M-4.19M-37.85M-7.13M-10.35M-12.26M-12.74M-10.80M-11.83M-12.39M
EBIT (Quarter)
-45.50M-55.80M-43.19M-44.62M-42.95M-40.43M-43.23M-47.30M-46.96M-62.41M-2.56M-4.19M-37.85M-7.13M-10.35M-12.26M-12.74M-10.80M-11.83M-12.39M
Non-operating items
Interest & Investment Income (Quarter)
-0.00M0.08M-0.20M-0.09M-0.12M-1.29M0.17M0.08M0.03M5.47M-0.08M-0.00M0.01M-0.06M-0.02M
Other Non Operating Income (Quarter)
-0.26M45.02M-0.82M-0.03M0.21M2.81M0.72M0.52M1.17M-18.19M0.03M0.07M0.03M0.06M0.19M0.91M0.85M0.80M0.98M0.87M
Non Operating Income (Quarter)
-0.84M-1.46M-0.23M-14.89M0.16M0.91M0.85M0.80M0.98M0.87M
Net income details
EBT (Quarter)
-45.51M163.07M-43.86M-44.49M-42.07M-38.55M-45.16M-45.27M-44.27M-245.43M-2.74M-4.69M-38.66M-8.44M-55.02M-14.38M-18.61M-10.80M-16.52M-15.08M
Tax Provisions (Quarter)
1.00M0.20M-35.67M-40.02M
Profit After Tax (Quarter)
-45.51M-57.94M-43.86M-44.64M-42.07M-38.11M-41.18M-45.27M-44.27M-59.72M-3.41M-5.65M-38.08M-22.03M-10.20M-11.35M-11.89M-9.97M-10.86M-11.54M
Income from Continuing Operations (Quarter)
-45.51M162.07M-43.86M-44.69M-42.07M-2.88M-45.16M-45.27M-44.27M-205.41M-2.74M-4.69M-38.66M-8.44M-55.02M-14.38M-18.61M-10.80M-16.52M-15.08M
Consolidated Net Income (Quarter)
-45.51M162.07M-43.86M-44.69M-42.07M-2.88M-45.16M-45.27M-44.27M-205.41M-2.74M-4.69M-38.66M-8.44M-55.02M-14.38M-18.61M-10.80M-16.52M-15.08M
Income towards Parent Company (Quarter)
-45.51M162.07M-43.86M-44.69M-42.07M-2.88M-45.16M-45.27M-44.27M-205.41M-2.74M-4.69M-38.66M-8.44M-55.02M-14.38M-18.61M-10.80M-16.52M-15.08M
Net Income towards Common Stockholders (Quarter)
-45.51M162.07M-43.86M-44.69M-42.07M-2.88M-45.16M-45.27M-44.27M-205.41M-2.74M-4.69M-38.66M-8.44M-55.02M-14.38M-18.61M-10.80M-16.52M-15.08M
Additional items
EPS (Basic) (Quarter)
-16.6259.37-15.76-15.94-11.39-0.86-11.13-11.00-8.94-45.40-0.55-0.94-7.71-1.69-13.57-0.77-1.00-0.71-0.70-0.63
EPS (Diluted) (Quarter)
-16.6259.37-15.76-15.94-11.39-0.86-11.13-11.00-8.94-45.40-0.55-0.94-7.71-1.69-13.57-0.77-1.00-0.71-0.70-0.63
Shares Outstanding (Quarter)
2.74M2.73M2.78M2.80M3.69M3.33M4.06M4.11M4.95M4.52M4.99M5.01M5.02M5.01M4.05M18.70M18.70M15.27M23.72M23.80M
Shares Outstanding (Diluted) (Quarter)
2.74M2.73M2.78M2.80M3.69M3.33M4.06M4.11M4.95M4.52M4.99M5.01M5.02M5.01M4.05M18.70M18.70M15.27M23.72M23.80M
EBITDA (Quarter)
-45.50M-55.80M-43.19M-44.62M-42.95M-40.43M-43.23M-47.30M-46.96M-62.41M-2.56M-4.19M-37.85M-7.13M-10.35M-12.26M-12.74M-10.80M-11.83M-12.39M
Interest Expenses (Quarter)
31.56M1.60M1.20M0.90M3.68M1.60M2.10M2.80M0.80M0.90M0.10M0.50M0.81M1.31M44.66M2.13M5.87M4.63M2.67M
Tax Rate (Quarter)
0.61-0.4592.5316.30